Diabetes
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
Showing 1–12 of 30 articles
Quick answer
NovaPharmaNews Diabetes hub for FDA covers 30 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Par Health Launches First Janumet XR Generic
FDA expands Tzield to certain pediatric patients with recent Stage 3 T1D
FDA Clears First OTC CGM for Children: Dexcom Expands Stelo
Chile warning labels on food: new evidence on efficacy and obesity risk
GLP-1 usage statistics show broad uptake and mixed clinical signals
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Eli Lilly Pipeline Deals and 2026 Outlook
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Lilly Retatrutide Phase 3 Safety Profile
Spotlight On: Four Things to Watch at ADA 2026
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.